HOOKIPA Pharma News

Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), RAPT Therapeutics (RAPT) and Hookipa Pharma (HOOK)

TipRanksMay 14 04:40 ET

HOOKIPA Pharma First Quarter 2024 Earnings: Beats Expectations

Yahoo FinanceMay 11 08:36 ET

RBC Capital Initiates a Buy Rating on Hookipa Pharma (HOOK)

TipRanksMay 10 06:41 ET

Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK) and Femasys (FEMY)

TipRanksMay 9 12:40 ET

HOOKIPA Pharma | 10-Q: Quarterly report

Futu NewsMay 9 07:07 ET · Announcements

Express News | HOOKIPA Pharma Inc - Restructuring Expenses Amounted to $1.3 Mln for Three Months Ended March 31, 2024

ReutersMay 9 07:05 ET

Express News | HOOKIPA Pharma Q1 Revenue USD 36.599 Million

ReutersMay 9 07:01 ET

Express News | HOOKIPA Pharma Q1 Net Income USD 14.383 Million

ReutersMay 9 07:01 ET

Express News | HOOKIPA Pharma Q1 Operating Expenses USD -25.493 Million

ReutersMay 9 07:01 ET

Express News | HOOKIPA Pharma Q1 Operating Income USD 11.106 Million

ReutersMay 9 07:01 ET

Express News | HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

ReutersMay 9 07:01 ET

HOOKIPA Pharma 1Q EPS 11c >HOOK

HOOKIPA Pharma 1Q EPS 11c >HOOK

Dow JonesMay 9 07:01 ET

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), BioMarin Pharmaceutical (BMRN) and Hookipa Pharma (HOOK)

TipRanksApr 30 02:12 ET

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Stock Catapults 25% Though Its Price And Business Still Lag The Industry

Despite an already strong run, HOOKIPA Pharma Inc. (NASDAQ:HOOK) shares have been powering on, with a gain of 25% in the last thirty days. Unfortunately, the gains of the last month did little to r

Simply Wall StApr 28 10:46 ET

Breaking Down HOOKIPA Pharma: 4 Analysts Share Their Views

Across the recent three months, 4 analysts have shared their insights on HOOKIPA Pharma (NASDAQ:HOOK), expressing a variety of opinions spanning from bullish to bearish.The table below provides a conc

BenzingaApr 26 08:00 ET

HOOKIPA Pharma Is Maintained at Buy by HC Wainwright & Co.

HOOKIPA Pharma Is Maintained at Buy by HC Wainwright & Co.

Dow JonesApr 26 07:05 ET

HOOKIPA Pharma Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/26/2024 524.92% HC Wainwright & Co. $6.5 → $5 Maintains Buy 03/25/2024 524.92% RBC Capital → $5 Reitera

BenzingaApr 26 06:52 ET

Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK), Praxis Precision Medicines (PRAX) and Blueprint Medicines (BPMC)

TipRanksApr 26 06:20 ET

Express News | HOOKIPA Pharma Inc. : H.c. Wainwright Cuts Target Price to $5 From $6.5

ReutersApr 26 06:04 ET

Express News | HOOKIPA Pharma Announced Its Final Pivotal Phase 2/3 Trial Design For HB-200 In Combination With Pembrolizumab Based On Alignment With The FDA

BenzingaApr 25 07:24 ET